Bio-FD&C Co Ltd
KOSDAQ:251120
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12 170
17 740
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bio-FD&C Co Ltd
Accounts Payable
Bio-FD&C Co Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bio-FD&C Co Ltd
KOSDAQ:251120
|
Accounts Payable
₩130.9m
|
CAGR 3-Years
117%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accounts Payable
₩50.9B
|
CAGR 3-Years
30%
|
CAGR 5-Years
4%
|
CAGR 10-Years
31%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Accounts Payable
₩3.4B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Accounts Payable
₩5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Accounts Payable
₩10.2B
|
CAGR 3-Years
77%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accounts Payable
₩993.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Bio-FD&C Co Ltd
Glance View
Bio-FD&C Co., Ltd. engages in the development of bio and health technologies. The company is headquartered in Incheon, Incheon and currently employs 61 full-time employees. The company went IPO on 2022-02-21. The firm is mainly engaged in the manufacture and sale of soybean callus culture extract, clock stem cell, centella asiatica, callus extract, aloe barbadensis phytoplaceta extract, prunus mume phytoplacenta extract, secale cereale adventitious root extract, acanthopanax koreanum adventitious root culture extract. The firm's products are mainly used as materials for cosmeceuticals, health functional foods and pharmaceuticals.
See Also
What is Bio-FD&C Co Ltd's Accounts Payable?
Accounts Payable
130.9m
KRW
Based on the financial report for Dec 31, 2023, Bio-FD&C Co Ltd's Accounts Payable amounts to 130.9m KRW.
What is Bio-FD&C Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
26%
Over the last year, the Accounts Payable growth was 104%. The average annual Accounts Payable growth rates for Bio-FD&C Co Ltd have been 117% over the past three years , 26% over the past five years .
You don't have any saved screeners yet
